Project: 3D cell culture platform for personalized ovarian cancer therapy selection.

Acronym 3D-SELECT (Reference Number: 113479)
Duration 01/10/2019 - 03/10/2022
Project Topic The consortium will deliver a platform (3D-SELECT) used for the selection of optimal and personalized ovarian cancer therapy. We will exploit cutting-edge 3D cell-culturing technology and artificial intelligence (AI) analytics to directly correlate the ex-vivo drug sensitivity of actual tumour biopsies with clinical outcome. The 3D-SELECT platform will enable high-throughput, automated and accurate screening of available drugs to significantly improve patient survival.
Network Eurostars 2
Call Eurostars Cut–off 11

Project partner

Number Name Role Country
1 VitroScan B.V. Coordinator Netherlands
2 AnaPath Services GmbH Partner Switzerland
3 Oncodia AB Partner Sweden
4 Uppsala University Partner Sweden
5 University of Applied Sciences Northwestern Switzerland Partner Switzerland
6 Robovision BVBA Partner Belgium